Autonomix Medical Reports New Topline Results From First 15 Patients' 7-Day Data Highlighting Significant Impact On Treatment Of Pancreatic Cancer Pain With Maintained Pain Reduction; 79% Responder Rate Achieved With Zero Opioid Use And Quality Of...
Autonomix Medical Reports New Topline Results From First 15 Patients' 7-Day Data Highlighting Significant Impact On Treatment Of Pancreatic Cancer Pain With Maintained Pain Reduction; 79% Responder Rate Achieved With Zero Opioid Use And Quality Of...
Autonomix Medical Reports New Topline Results From First 15 Patients' 7-Day Data Highlighting Significant Impact On Treatment Of Pancreatic Cancer Pain With Maintained Pain Reduction; 79% Responder Rate Achieved With Zero Opioid Use And Quality Of Life Improvement At 7 Days Post-Procedure; Clinically Meaningful Mean Of 4.96 Or 63% Reduction Of Pain On The VAS Pain Scale Was Observed
Autonomix Medical报告了前15名患者的7天数据的新主要结果，这些结果突出显示了持续减轻疼痛对胰腺癌疼痛治疗的重大影响；术后7天零使用阿片类药物和生活质量改善实现了79％的反应率；在VAS疼痛量表上观察到具有临床意义的平均疼痛减轻了4.96％或63％
79% responder rate achieved with zero opioid use and quality of life improvement at 7 days post-procedure
术后7天内，阿片类药物使用率为零，生活质量得到改善，反应率达到79％
Company reaches 60% enrollment with 15 patients1 successfully enrolled; No unexpected complications or procedural-related significant adverse events
公司入组人数达到 60%，成功入组了15名患者1；没有意外并发症或与手术相关的重大不良事件
Clinically meaningful mean of 4.96 or 63% reduction of pain on the VAS pain scale was observed
在 VAS 疼痛量表上观察到的具有临床意义的平均疼痛减轻幅度为 4.96% 或 63%
THE WOODLANDS, TX, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced preliminary positive results from the first 15 patients in the Company's ongoing proof-of-concept human clinical trial (the "Trial") evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.
德克萨斯州伍德兰兹，2024年10月31日（GLOBE NEWSWIRE）——Autonomix Medical, Inc.（纳斯达克股票代码：AMIX）（“Autonomix” 或 “公司”）是一家专注于推进创新技术以彻底改变神经系统疾病的诊断和治疗方式的医疗器械公司，今天宣布了该公司正在进行的概念验证人体临床试验（“试验”）中首批15名患者的初步阳性结果输送经血管能量以消融相关神经问题并减轻患者疼痛的安全性和有效性伴有胰腺癌疼痛。
